AAOpt 2024: Keeping contact lens wearers comfortable with Miebo

News
Video

David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.

David Geffen, OD, FAAO presented on his research using the eye drop perfluorohexyloctane, also known as Miebo, for contact lens wearers. His poster was titled, "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers."

Geffen explained that one of the main reasons for contact lens dropout is dry eye and discomfort. His study enrolled 46 contact lens wearers - 26 daily wearers and 20 monthly wearers - and had them use the Mibo drops 4 times per day for 30 days. The study looked at various metrics like meibomian scores, staining, visual acuity, osmolarity, and contact lens comfort. Surprisingly, the only statistically significant change was an increase in contact lens comfort. Geffen noted that most of the study participants continued using the drops with their contacts after the study concluded. Based on these findings, Geffen believes Mibo could be a valuable tool for improving contact lens retention and reducing dropouts due to discomfort. He stated that plans should be made to conduct further studies to see if the drops can be used directly on the contact lenses without any issues.

Currently, Geffen and many of his colleagues are already using Miebo off-label for contact lens patients, with good results. The main considerations are ensuring patients use the right drop size and frequency (2-3 times per day may be sufficient). Overall, there is an exciting potential new application for Mibo that could transform the contact lens experience for many patients. While more research is needed, the initial findings are very promising in terms of improving comfort and potentially reducing contact lens dropout rates long-term.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Karl Stonecipher ASCRS 2025
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
© 2025 MJH Life Sciences

All rights reserved.